HomeAI · summaries
Storia in 4 fonti
In Depth: U.S.’ Biotech Scrutiny Tests China’s Drugmakers Abroad
Chinese pharma companies are still striking global deals, but rising regulatory pressure is forcing buyers and sellers to rethink price, structure and risk
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
BIO board spoke with national security, health officials on China, CEO says
BIO makes China political strategy a top priority as US weighs outbound investment limits; CEO Crowley says biotech may fall under COINS Act.
- ·
statnews.com
Biosecure didn’t stop China’s rise in biotech. Some lawmakers want to do more
They're laying the groundwork for legislation and regulation to counter Chinese biopharma companies.
- ·
caixinglobal.com
In Depth: U.S.’ Biotech Scrutiny Tests China’s Drugmakers Abroad
Chinese pharma companies are still striking global deals, but rising regulatory pressure is forcing buyers and sellers to rethink price, structure and risk
- ·
biopharmadive.com
At BIO, tension over China biotech deal regulation looms
Biotech investors, executives and analysts worry that blanket bans on deals with Chinese companies could curb domestic entrepreneurs’ ambitions in the sector.